Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Destiny Pharma Ltd
Destiny Pharma Ltd
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Drug Delivery
Positive update on the development of new XF‐platform drug formulations
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections
Research & Development
Destiny Pharma secures £1.6 million grant to fight microbial resistance
The UK-China antimicrobial resistance programme has allocated grant to research its novel XF drugs
Recruitment
Nick Rodgers joins Destiny Pharma
Research & Development
Destiny Pharma announces research collaboration with Aston University
Partnership will see a dedicated team investigate potential antimicrobial candidates against biofilms
Media
Destiny Pharma establishes Scientific Advisory Board
Pharmaceutical
Destiny Pharma appoints Neil Clark new CEO
Bill Love, Destiny’s founder, to become Chief Scientific Officer
Ingredients
Destiny Pharma receives US FDA QIDP designation for novel antibacterial product
Lead drug product in development for the prevention of post-surgical Staphyloccocal infections
Subscribe now